COST-EFFECTIVENESS OF METFORMIN-GLIMEPIRIDE COMBINATION COMPARED TO SINGLE METFORMIN USE IN DECREASING 2 H POST PRANDIAL BLOOD GLUCOSE

Q2 Pharmacology, Toxicology and Pharmaceutics

International Journal of Applied Pharmaceutics Pub Date : 2024-02-15 DOI:10.22159/ijap.2024.v16s1.10

Najmiatul Fitria, Mila Andela, Resna Rerita, Hansen Nasif

{"title":"COST-EFFECTIVENESS OF METFORMIN-GLIMEPIRIDE COMBINATION COMPARED TO SINGLE METFORMIN USE IN DECREASING 2 H POST PRANDIAL BLOOD GLUCOSE","authors":"Najmiatul Fitria, Mila Andela, Resna Rerita, Hansen Nasif","doi":"10.22159/ijap.2024.v16s1.10","DOIUrl":null,"url":null,"abstract":"Objective: Complications related to diabetes could reduce the quality of life. In Indonesia, the costs incurred for diabetes mellitus annually will increase as complications of the disease increase. This study explored the cost-effectiveness therapy of metformin-glimepiride combination on post-prandial blood glucose. \nMethods: Glimepiride is added to the first category for diabetes mellitus receiving metformin to improve blood sugar levels and reduce costs. An observational study was conducted retrospectively to analyze post-prandial blood sugar levels with the total direct medical costs at Universitas Andalas Hospital. The study involved 114 medical records of patients referred during 2021. The combination of Metformin HCL and Glimepiride was compared to Metformin alone in measuring cost and effect parameters. The categorical dependent-independent groups were statistically analyzed using Chi-square, while the cost and effect parameters were calculated to get the Incremental Cost-Effectiveness Ratio (ICER) value. \nResults: There were no significant differences between groups on sociodemographic characteristics (p<0.05). An incremental cost value of IDR 43,291 was obtained for reducing post-prandial blood sugar by 21.92 mg/dl. \nConclusion: Increasing cost and effect parameters require further analysis to determine the trade-off point.","PeriodicalId":13737,"journal":{"name":"International Journal of Applied Pharmaceutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Applied Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ijap.2024.v16s1.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Complications related to diabetes could reduce the quality of life. In Indonesia, the costs incurred for diabetes mellitus annually will increase as complications of the disease increase. This study explored the cost-effectiveness therapy of metformin-glimepiride combination on post-prandial blood glucose. Methods: Glimepiride is added to the first category for diabetes mellitus receiving metformin to improve blood sugar levels and reduce costs. An observational study was conducted retrospectively to analyze post-prandial blood sugar levels with the total direct medical costs at Universitas Andalas Hospital. The study involved 114 medical records of patients referred during 2021. The combination of Metformin HCL and Glimepiride was compared to Metformin alone in measuring cost and effect parameters. The categorical dependent-independent groups were statistically analyzed using Chi-square, while the cost and effect parameters were calculated to get the Incremental Cost-Effectiveness Ratio (ICER) value. Results: There were no significant differences between groups on sociodemographic characteristics (p<0.05). An incremental cost value of IDR 43,291 was obtained for reducing post-prandial blood sugar by 21.92 mg/dl. Conclusion: Increasing cost and effect parameters require further analysis to determine the trade-off point.

查看原文本刊更多论文

二甲双胍-格列美脲复方制剂与单用二甲双胍在降低餐前 2 小时血糖方面的成本效益比较

目的糖尿病并发症会降低生活质量。在印度尼西亚，随着糖尿病并发症的增加，每年因糖尿病产生的费用也会增加。本研究探讨了二甲双胍-格列美脲联合治疗餐后血糖的成本效益疗法。方法：格列美脲被添加到接受二甲双胍治疗的第一类糖尿病患者中，以改善血糖水平并降低成本。安达卢西亚大学医院开展了一项回顾性观察研究，分析餐后血糖水平和直接医疗总费用。研究涉及 2021 年期间转诊的 114 名患者的医疗记录。在衡量成本和效果参数时，将二甲双胍盐酸盐和格列美脲联合用药与二甲双胍单独用药进行了比较。采用卡方（Chi-square）对依赖组和非依赖组进行统计分析，同时计算成本和效果参数，得出增量成本效益比（ICER）值。结果各组在社会人口学特征方面无明显差异（P<0.05）。餐后血糖降低 21.92 mg/dl 的增量成本值为 43,291 印度卢比。结论：增加成本和效果参数需要进一步分析，以确定权衡点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Applied Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

1.40

自引率

0.00%

发文量

219

期刊介绍： International Journal of Applied Pharmaceutics (Int J App Pharm) is a peer-reviewed, bimonthly (onward March 2017) open access journal devoted to the excellence and research in the pure pharmaceutics. This Journal publishes original research work that contributes significantly to further the scientific knowledge in conventional dosage forms, formulation development and characterization, controlled and novel drug delivery, biopharmaceutics, pharmacokinetics, molecular drug design, polymer-based drug delivery, nanotechnology, nanocarrier based drug delivery, novel routes and modes of delivery; responsive delivery systems, prodrug design, development and characterization of the targeted drug delivery systems, ligand carrier interactions etc. However, the other areas which are related to the pharmaceutics are also entertained includes physical pharmacy and API (active pharmaceutical ingredients) analysis. The Journal publishes original research work either as a Original Article or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication in the Journal.